Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready‐to‐use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin‐induced severe hypoglycaemia in adults with type 1 diabetes

Pieber, Thomas R.; Aronson, Ronnie; Christiansen, Mark P.; Bode, Bruce; Junaidi, Khaled; Conoscenti, Valentina

doi:10.1111/dom.14699

Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready‐to‐use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin‐induced severe hypoglycaemia in adults with type 1 diabetes

Glucagon is indicated for the treatment of persons living with diabetes who have hypoglycaemia and are unable or unwilling to consume carbohydrates. The primary study objective was to determine whether ready-to-use, room temperature liquid stable glucagon (Gvoke Prescribing Information; Xeris Pha…